Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with multiple well-established, generic treatment options including antidepressants (e.g., tricyclic antidepressants, serotonin / norepinephrine reuptake inhibitors), antiepileptic drugs (e.g., gabapentin), nonsteroidal anti-inflammatory drugs (NSAIDs), and opioid-based drugs. However, current analgesics do not offer adequate pain relief to all patients, leaving unmet need and opportunity for new options, especially novel mechanisms of action. The early PDN pipeline is large and diverse, and Vertex’s novel Nav1.8 inhibitor Journavx (suzetrigine) is in Phase 3 development for PDN. The successful launch of a novel analgesic will require a granular understanding of treatment patterns in this crowded and highly generic market.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PDN patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PDN patients?
- What percentage of PDN patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of PDN patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key companies: AbbVie, Almatica, Aucta, Averitas, Azurity, BioDelivery Sciences International, Collegium Pharmaceuticals, Kowa, Protega Pharmaceuticals, Sumitomo Pharma, Vertex, Viatris
Key drugs: Gabapentin (Neurontin, generics), tramadol, duloxetine (Cymbalta, generics), pregabalin (Lyrica, generics), Motpoly XR, other antidepressants (e.g., amitriptyline, citalopram, escitalopram), other AEDS (e.g., carbamazepine, topiramate), oral NSAIDs, opioid analgesics (e.g., Belbuca, RoxyBond, Xtampza ER), Qutenza, Gralise, Horizant, Nucynta, ZTlido, Journavx
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
